329.83
+0.09(+0.03%)
Currency In USD
Address
99 High Street
Boston, MA 02110
United States of America
Phone
857 449 2244
Website
Sector
Healthcare
Industry
Biotechnology
Employees
339
First IPO Date
June 28, 2019
| Name | Title | Pay | Year Born |
| Mr. William Meury | President, Chief Executive Officer & Director | 0 | 1968 |
| Dr. Stephen K. Brannan | Chief Medical Officer | 751,750 | 1956 |
| Dr. Andrew Craig Miller Ph.D. | Founder and President of Research & Development | 835,400 | 1982 |
| Ms. Mia Kelley J.D. | General Counsel | 0 | N/A |
| Mr. Frank Truslow | Senior Vice President of Corporate Development | 0 | N/A |
| Ms. Alexis Smith | Vice President of Corporate Affairs & Investor Relations | 0 | N/A |
| Mr. Jonathan Rosin | Chief Human Resources Officer | 0 | N/A |
| Mr. Jason Parker Brown | Chief Financial Officer | 0 | 1988 |
| Dr. Alan Breier | Chair of Scientific Advisory Board & Chief Clinical Advisor | 0 | N/A |
| Dr. Ronald N. Marcus M.D. | Senior Vice President of Medical | 0 | 1958 |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.